Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mitchell Ross (NPI 1275995540)

Field	Value
Entity Type	Individual
Organization	Mitchell Ross
Address	3232 N Northhills Blvd
City	Fayetteville
State	AR
ZIP	72703
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 24, 2016

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the datasets: lifetime Medicare revenue is $2.2M and there is no Medicaid billing on file, so Medicaid does not appear in the provider’s payer mix and Medicare accounts for the entirety of reported public-payer revenue. Analysts should treat this profile as Medicare‑centric when benchmarking payment or access questions.

Revenue is highly concentrated in a small set of oncology biologics and immunotherapies: the precomputed top‑3 Medicare codes account for 58.1% of total Medicare revenue, with J9144, J9271, and J9299 together driving the majority of payments. That concentration indicates the practice’s revenue base is driven by high‑use injectable oncology agents rather than broad ancillary or primary‑care services.

The code mix and volumes point to an infusion‑centric hematology/oncology operation: high counts for infusion and oncology drug codes (e.g., J9299 with 15.5K claims and $371.5K revenue, J9144 with 10.4K claims and $396.7K revenue, and J9271 with 9.4K claims and $394.8K revenue) together with chemotherapy administration codes (96413, 96365, 96367) suggest routine on‑site administration of systemic cancer therapies. Supportive care agents (J1561 immune globulin, Q5115 pegfilgrastim) and high volumes of E/M codes further imply bundled clinic workflows combining infusions and medical management.

Competitive standing on the headline drugs is mixed: J9144 ranks #191 of 615 providers nationally (67th percentile; typical, unremarkable volume for this code) indicating a modest national footprint for daratumumab; J9271 ranks #1254 of 1841 (31th percentile; typical, unremarkable volume) showing lower relative use of pembrolizumab; and J9299 ranks #237 of 505 (53th percentile; typical, unremarkable volume) reflecting a mid‑range national presence for nivolumab. Overall these ranks characterize the provider as a modest-to-moderate national participant for its top oncology injectables rather than a dominant national outlier.

There are several procedure and lab volumes that are unusually high relative to national peers for non‑drug services: 99215 ranks #6341 of 145531 providers nationally (96th percentile; notably above typical national volume for this code), 80053 ranks in the 96th percentile, and 85025 is in the 95th percentile (all labeled as typical or notably above typical where provided). These elevated percentiles for high‑acuity E/M and routine lab panels suggest the practice bills more complex office visits and monitoring than many peers, consistent with management of active oncology patients.

Some non‑drug items reinforce an integrated cancer care model with on‑site diagnostics: PET/CT activity is present (78815: 75 claims, $74.6K revenue; 78816: 13 claims, $12.9K revenue; A9552: 74 claims, $11.6K revenue), indicating the provider either performs or bills for advanced imaging in the cancer workup and surveillance pathway. The presence of imaging revenue alongside infusion and E/M services supports a workflow where diagnostics and therapeutics are coordinated in the ambulatory oncology setting.

Certain biosimilars and supportive agents show uneven national positioning: J1561 (immune globulin) ranks #42 of 180 providers (77th percentile; typical, unremarkable volume), indicating relatively strong use among peers, while Q5115 (pegfilgrastim biosimilar) ranks #106 of 125 providers (14th percentile; typical, unremarkable volume), reflecting limited use of that specific biosimilar product. This mix suggests selective adoption or referral patterns for some supportive agents rather than uniform uptake across all biosimilar options.

The provider’s enrollment history shows sustained presence: the NPI was enumerated on 2016-03-24 (~10 years ago), which provides a multi‑year track record for trend analysis and suggests enough tenure to evaluate longitudinal shifts in drug mix, visit acuity, or referral relationships within the Medicare data.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

108 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	10,440	$40	$396.7K
J9271	Injection, pembrolizumab, 1 mg	9,400	$40	$394.8K
J9299	Injection, nivolumab, 1 mg	15,480	$20	$371.5K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	7,670	$40	$283.8K
J0897	Injection, denosumab, 1 mg	6,540	$20	$117.7K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	2,410	$30	$81.9K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	80	$990	$74.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	480	$90	$40.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	290	$130	$37K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	360	$90	$32.4K

Showing 1–10 of 108

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 108 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Mitchell Ross — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

108 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	37	40	20,700	$40	$896.3K
J9299	16	30	15,660	$20	$432.9K
J9144	7	10	10,530	$40	$361.9K
J1561	3	10	5,930	$40	$216.4K
Q5115	16	20	2,800	$30	$95.9K
J0897	39	160	2,580	$20	$89.7K
78815	55	100	90	$550	$83.7K
J0885	34	40	4,070	$10	$38K
96413	34	80	380	$90	$36.6K
A9552	26	40	180	$150	$28.9K

Showing 1–10 of 108

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mitchell Ross, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Shore Hematology Oncology Associates PC	NY	Specialist	$0	$61.9M
Highlands Oncology Group PA	AR	Hematology & Oncology Physician	$0	$5.7M
Matthew Lockwood	AR	Hematology & Oncology Physician	$4.2M	$0
Eric Schaefer	AR	Hematology & Oncology Physician	$3.6M	$0
Patrick Travis	AR	Hematology & Oncology Physician	$3.3M	$0
K'anne Arthur	AR	Hematology & Oncology Physician	$3.2M	$0
Gregory Oakhill	AR	Hematology & Oncology Physician	$2.8M	$0
Stephan Rosenfeld	AR	Hematology & Oncology Physician	$2.3M	$0
J Beck	AR	Hematology & Oncology Physician	$2.2M	$0
Dmitriy Zak	AR	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Mitchell Ross, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sanders, Tompkins, Schiro, Landers And Sanders PLLC	AR	Pediatric Dentistry	$0	$30.4M
Children's Therapy Services, Inc.	AR	Pediatric Physical Therapist	$0	$29.2M
Life Styles Inc.	AR	Case Management Agency	$0	$19.6M
Washington Regional Medical Center	AR	General Acute Care Hospital	$0	$10.9M
Cross Therapy Services, Ltd	AR	Pediatric Occupational Therapist	$0	$5.8M
Medical Associates Of Northwest Arkansas PA	AR	Pediatrics Physician	$0	$5.8M
Oral & Facial Surgery Center PA	AR	Oral and Maxillofacial Surgery (Dentist)	$0	$4.8M
Thomas A. Sarna, Dds PLLC	AR	Oral and Maxillofacial Surgery Clinic/Center	$0	$3.4M
Washington Regional Medical System	AR	Hospitalist Physician	$0	$3.4M
The Therapy Spot,llc	AR	Speech-Language Pathologist	$0	$3.2M

Mitchell Ross — Billing Profile & Reimbursement Data

Sign up for Mitchell Ross — Billing Profile & Reimbursement Data policy alerts

Mitchell Ross — Billing Profile & Reimbursement Data

Sign up for Mitchell Ross — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References